Since, we found that all patients with BRCA2 mutant cancers in the COH cohort achieved pCR (table S2), and all our subsequent analyses also showed improved outcomes in BRCA2 mutant cancers (table S3), we grouped TNBCs harboring BRCA1 and BRCA2 pathogenic mutations together as BRCAmut cancers. This evidence concerns the gene BRCA2 and cancer.